Janney Montgomery Scott LLC purchased a new position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 61,319 shares of the company’s stock, valued at approximately $913,000.
Several other institutional investors also recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new stake in Elanco Animal Health in the 3rd quarter valued at $95,000. HBK Sorce Advisory LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at about $169,000. C M Bidwell & Associates Ltd. bought a new stake in Elanco Animal Health in the third quarter valued at about $129,000. Allspring Global Investments Holdings LLC increased its holdings in Elanco Animal Health by 10.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after purchasing an additional 1,127 shares during the last quarter. Finally, Innovis Asset Management LLC bought a new stake in Elanco Animal Health in the third quarter valued at about $144,000. 97.48% of the stock is owned by institutional investors.
Insider Activity at Elanco Animal Health
In other news, Director R David Hoover acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director R David Hoover bought 20,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director William F. Doyle bought 15,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were bought at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the acquisition, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.
Elanco Animal Health Price Performance
Elanco Animal Health stock opened at $17.58 on Friday. The stock’s fifty day moving average price is $15.30 and its two-hundred day moving average price is $14.85. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $17.82. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. The firm has a market cap of $8.69 billion, a PE ratio of -6.63, a price-to-earnings-growth ratio of 1.66 and a beta of 1.34.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.93 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on ELAN shares. Morgan Stanley increased their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Barclays increased their price target on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. The Goldman Sachs Group upped their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research note on Tuesday, February 27th. Finally, Piper Sandler restated a “neutral” rating and issued a $19.00 price objective (up previously from $18.00) on shares of Elanco Animal Health in a research note on Monday, May 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.29.
Check Out Our Latest Stock Analysis on Elanco Animal Health
Elanco Animal Health Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- Industrial Products Stocks Investing
- Pure Storage Stock Spikes and Analysts are Jumping on Board
- What Are Dividend Champions? How to Invest in the Champions
- 3 Penny Stocks Trading Abnormal Volume Today
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Salesforce Falls 25% Into A Once in a Lifetime Opportunity
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
